# NCT02484404 (NCT02484404)

> Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

No report yet. It can be ordered.

- Drugs tested: durvalumab plus olaparib; durvalumab plus cediranib; durvalumab plus olaparib plus cediranib
- Indication: advanced solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02484404
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Colorectal Neoplasms; Breast Neoplasms
- Interventions: Olaparib; Cediranib; Durvalumab
- Enrollment: 268
- Primary outcome: Ph II Determine overall response rate of Durvalumab-O and Durvalumab-C in patients with recurrent ovarian cancer
- Primary outcome: Ph I Determine the recommended phase II dose (RP2D) and the safety of doublet therapies of Durvalumab/olaparib (Durvalumab-O) and Durvalumab/cediranib (Durvalumab-C) in patients with advanced solid tumors

## Indexed commentary on NCT02484404 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02484404